Search clinical trials for: GW823296

Total 8 results

GlaxoSmithKline

Completed

GW823296 Repeat Dose Study In Healthy Male And Female Subjects

Healthy Subjects

Australia
GlaxoSmithKline

Completed

Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder

Post-Traumatic Stress Disorder

United States
GlaxoSmithKline

Terminated

A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder (Orvepitant MDD)

Depressive Disorder

United States, Canada
GlaxoSmithKline

Terminated

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder (orvepitant MDD)

Depressive Disorder, Major

United States, Canada
GlaxoSmithKline

Completed

A New Oral Treatment For Type II Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Germany, Canada, Sweden, Latvia, Finland, Greece, Romania, Czechia, Puerto Rico
GlaxoSmithKline

Withdrawn

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)

Depressive Disorder

Germany

3

Subscribe